Preventing Superbugs and Protecting Patients Act

1/11/2023, 1:31 PM

Congressional Summary of S 2503

Preventing Superbugs and Protecting Patients Act

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to identify types of medical devices for which premarket notification must include proposed labeling, including validated instructions regarding cleaning, disinfection, and sterilization.

(Sec. 3) The FDA must issue final guidance regarding when a premarket notification is required for a modification to a medical device.

Current Status of Bill S 2503

Bill S 2503 is currently in the status of Bill Introduced since February 4, 2016. Bill S 2503 was introduced during Congress 114 and was introduced to the Senate on February 4, 2016.  Bill S 2503's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 417. as of April 5, 2016

Bipartisan Support of Bill S 2503

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 2503

Primary Policy Focus

Health

Potential Impact Areas

Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government information and archivesHealth technology, devices, suppliesInfectious and parasitic diseases

Alternate Title(s) of Bill S 2503

Preventing Superbugs and Protecting Patients ActA bill to establish requirements for reusable medical devices relating to cleaning instructions and validation data, and for other purposes.Preventing Superbugs and Protecting Patients ActPreventing Superbugs and Protecting Patients Act
Start holding our government accountable!

Comments